In many cancers, particularly neuroendocrine tumors, the expression of SSTRs is significantly reduced.523 SSTR2 is the most studied receptor, primarily inhibiting tumor growth by suppressing cell proliferation signaling pathways (such as PI3K/AKT and MAPK) and activating apoptotic pathways (such as p53). Here, AKT1 is linked to cancer.